Published in Medical Letter on the CDC and FDA, July 3rd, 2005
Study 1: Peritransplant immuno-adsorption enables transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients.
"Kidney transplant recipients with a current positive complement- dependent cytotoxicity crossmatch (CDCXM) are at high risk for hyperacute rejection and graft loss. Immuno-adsorption (IA) represents an efficient strategy to remove donor-specific allo-antibodies. In this analysis, we evaluated effectiveness of peritransplant IA as an anti-humoral strategy to overcome a current positive CDCXM in presensitized...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA